ICH Guideline for Elemental Impurities Moves to Step 2b - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ICH Guideline for Elemental Impurities Moves to Step 2b
A proposed new guideline provides a global policy for limiting metal impurities qualitatively and quantitatively in drug products and ingredients.


The International Conference on Harmonization (ICH) reports that the ICH Q3D Impurities: Guideline for Elemental Impurities reached Step 2b of the ICH process in July 2013 and now enters the consultation period (i.e., Step 3). The formal ICH procedure consists of five steps: Step 1 Consensus Building; Step 2 Confirmation of Six-Party Consensus; Step 3 Regulatory Consultation and Discussion; Step 4 Adoption of an ICH Harmonized Tripartite Guideline; and Step 5 Implementation.

The proposed new guideline provides a global policy for limiting metal impurities qualitatively and quantitatively in drug products and ingredients. The existing ICH Q3A guideline classifies impurities as organic, inorganic, and residual solvents. The Q3A and Q3B guidelines address the requirements for organic impurities. An additional ICH guideline, Q3C, was developed to provide clarification of the requirements for residual solvents. The proposed new guideline, ICH Q3D would provide similar clarification of the requirements for metals, which are included in the ICH inorganic impurities classification.

Comments on the draft guideline may be submitted to the ICH Secretariat. Stakeholders from the European Union, the United States, and Japan are encouraged to submit their comments to their respective regulatory authorities.

Sources
ICH, “ICH Q3D Guideline Reaches Step 2b of the ICH Process,” Press Release, Aug. 5,  2013.

ICH, Q3D Impurities: Guideline for Elemental Impurities, Step 2b version, July 26, 2013.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing

Click here